Private equity firm buys Tanzania’s generic drug maker Zenufa for undisclosed price

Catalyst Principal Partners, a private equity firm focused on East Africa, has picked up Zenufa Laboratories, Tanzania’s second-largest generic drug maker.

Terms of the deal weren’t disclosed.

Zenufa manufactures a wide range of over-the-counter and prescription medicines for the Tanzanian market, and was the first facility in the country to be  certified as 100% cGMP compliant.

Survey

Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

“While the healthcare sector remains dominated by foreign imports representing majority of Tanzania’s medicine supply, as an established local pharmaceutical manufacturer, Zenufa is uniquely positioned to meet the rising healthcare needs of the population through offering affordable, quality medication manufactured to the highest international best practice standards,” Martha Osier, a Catalyst investment manager, said in a statement.

The Zenufa purchase represents Catalyst’s fourth investment in Tanzania and its second in the healthcare sector. It bought Mimosa Pharmacy in 2014, which now operates under the name “Goodlife Pharmacy” and is rapidly expanding its pharmacy retail business.

- here’s the release

Related Article:
Tanzania, like GlaxoSmithKline, learns delivery tricks from Coke

Suggested Articles

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.

Pfizer is ponying up $500 million on top of $100 million already committed to a gene therapy manufacturing facility in North Carolina.